FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890864206> ?p ?o ?g. }

• W2890864206 endingPage "89" @default.
• W2890864206 startingPage "83" @default.
• W2890864206 abstract "Carboplatin is the milestone of epithelial ovarian cancer (EOC) treatment, thus response to platinum is the major prognostic factor. Among platinum-sensitive patients, 40% carry a germline or somatic BRCA1/2 mutation. In this scenario a new class of drugs, the PARP inhibitors (PARPis), produced a significant improvement in long-term disease control. In order to make an aggregate evaluation of the impact of these agents, we performed a systematic review and meta-analysis. Clinical trials were selected by searching “Pubmed” database and abstracts from major cancer meetings. We considered the January 2008 - April 2018 time frame. Progression free survival (PFS) was the primary end-point, toxicities were secondary end-points. Hazard ratios (HRs) of PFS, with confidence intervals, and risk ratios of grade 3–4 toxicity rates, were extracted from retrieved studies and included in the current analysis. Meta-analysis was carried out by the fixed and random effect models. We conducted this meta-analysis to also compare indirectly the efficacy of different PARPis in EOC patients. Five randomized trials for a total of 1839 patients were selected and included in the final analysis. In particular, we evaluated a BRCA-mutant cohort (871 patients) with a pooled HR 0.25 (95%CI 0.21-0.31) and the BRCA-wild type cohort (836 patients) with a pooled HR 0.41 (95%CI 0.31-0.55), respectively. Regarding safety profile, no significant differences were detected in all grade toxicities, however, taking into account 3–4 grade toxicities and SAEs (severe adverse events), we show that rucaparib-treated patients reported major abdominal pain events, while niraparib-treated patients were associated with the highest percentage of haematological toxicities, hypothesizing a drug effect for the safety analysis. In the indirect comparisons, significant differences were not detected on PFS for the different agents. We confirm a significant benefit in survival outcome of PARPis for EOC patients with a “class effect” on the bases of narrow CI and indirect comparisons in the different groups. Therefore, we underline that this strategy is of special value in BRCA-mutated patients because genetic testing allows best patient selection for all PARPis with the added value of individualized prevention in familiars." @default.
• W2890864206 created "2018-09-27" @default.
• W2890864206 creator A5000779766 @default.
• W2890864206 creator A5000930768 @default.
• W2890864206 creator A5017866134 @default.
• W2890864206 creator A5026847949 @default.
• W2890864206 creator A5029086187 @default.
• W2890864206 creator A5032844457 @default.
• W2890864206 creator A5037451718 @default.
• W2890864206 creator A5057162212 @default.
• W2890864206 creator A5058197744 @default.
• W2890864206 creator A5073842215 @default.
• W2890864206 creator A5081108017 @default.
• W2890864206 date "2018-11-01" @default.
• W2890864206 modified "2023-10-07" @default.
• W2890864206 title "The Era of PARP inhibitors in ovarian cancer: “Class Action” or not? A systematic review and meta-analysis" @default.
• W2890864206 cites W1770529458 @default.
• W2890864206 cites W1858735449 @default.
• W2890864206 cites W1968578664 @default.
• W2890864206 cites W1974756790 @default.
• W2890864206 cites W1984108427 @default.
• W2890864206 cites W1994898034 @default.
• W2890864206 cites W1995808879 @default.
• W2890864206 cites W2004144597 @default.
• W2890864206 cites W2017937144 @default.
• W2890864206 cites W2020144275 @default.
• W2890864206 cites W2024825120 @default.
• W2890864206 cites W2028991902 @default.
• W2890864206 cites W2033816200 @default.
• W2890864206 cites W2050118439 @default.
• W2890864206 cites W2056920544 @default.
• W2890864206 cites W2075642745 @default.
• W2890864206 cites W2075645293 @default.
• W2890864206 cites W2088428206 @default.
• W2890864206 cites W2089179821 @default.
• W2890864206 cites W2106157865 @default.
• W2890864206 cites W2114220172 @default.
• W2890864206 cites W2123696077 @default.
• W2890864206 cites W2126280475 @default.
• W2890864206 cites W2138733479 @default.
• W2890864206 cites W2144373793 @default.
• W2890864206 cites W2145807414 @default.
• W2890864206 cites W2160466424 @default.
• W2890864206 cites W2162163297 @default.
• W2890864206 cites W2162393230 @default.
• W2890864206 cites W2169102956 @default.
• W2890864206 cites W2169205464 @default.
• W2890864206 cites W2255146166 @default.
• W2890864206 cites W2286059102 @default.
• W2890864206 cites W2400651373 @default.
• W2890864206 cites W2409819001 @default.
• W2890864206 cites W2413417474 @default.
• W2890864206 cites W2523859159 @default.
• W2890864206 cites W2528228811 @default.
• W2890864206 cites W2530146471 @default.
• W2890864206 cites W2548938412 @default.
• W2890864206 cites W2584184455 @default.
• W2890864206 cites W2589382098 @default.
• W2890864206 cites W2591608295 @default.
• W2890864206 cites W2611302285 @default.
• W2890864206 cites W2737389832 @default.
• W2890864206 cites W2754327139 @default.
• W2890864206 cites W2763321107 @default.
• W2890864206 cites W2768943365 @default.
• W2890864206 cites W2789374297 @default.
• W2890864206 cites W2789851018 @default.
• W2890864206 cites W2795391593 @default.
• W2890864206 cites W4210987384 @default.
• W2890864206 doi "https://doi.org/10.1016/j.critrevonc.2018.08.011" @default.
• W2890864206 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30293710" @default.
• W2890864206 hasPublicationYear "2018" @default.
• W2890864206 type Work @default.
• W2890864206 sameAs 2890864206 @default.
• W2890864206 citedByCount "34" @default.
• W2890864206 countsByYear W28908642062019 @default.
• W2890864206 countsByYear W28908642062020 @default.
• W2890864206 countsByYear W28908642062021 @default.
• W2890864206 countsByYear W28908642062022 @default.
• W2890864206 countsByYear W28908642062023 @default.
• W2890864206 crossrefType "journal-article" @default.
• W2890864206 hasAuthorship W2890864206A5000779766 @default.
• W2890864206 hasAuthorship W2890864206A5000930768 @default.
• W2890864206 hasAuthorship W2890864206A5017866134 @default.
• W2890864206 hasAuthorship W2890864206A5026847949 @default.
• W2890864206 hasAuthorship W2890864206A5029086187 @default.
• W2890864206 hasAuthorship W2890864206A5032844457 @default.
• W2890864206 hasAuthorship W2890864206A5037451718 @default.
• W2890864206 hasAuthorship W2890864206A5057162212 @default.
• W2890864206 hasAuthorship W2890864206A5058197744 @default.
• W2890864206 hasAuthorship W2890864206A5073842215 @default.
• W2890864206 hasAuthorship W2890864206A5081108017 @default.
• W2890864206 hasBestOaLocation W28908642062 @default.
• W2890864206 hasConcept C121608353 @default.
• W2890864206 hasConcept C126322002 @default.
• W2890864206 hasConcept C143998085 @default.
• W2890864206 hasConcept C197934379 @default.
• W2890864206 hasConcept C207103383 @default.
• W2890864206 hasConcept C2776694085 @default.

• next